Journal Mobile Options
Table of Contents
Vol. 82, No. 4, 2009
Issue release date: June 2009
Urol Int 2009;82:459–463
(DOI:10.1159/000218538)

Role of Calcium in the Aggregation of Particles Coated by Urinary Macromolecules

Baumann J.M. · Affolter B. · Caprez U. · Clivaz C. · von Arx U.
aStone Research Center Viollier, and bBern University of Applied Sciences, Division of Architecture, Wood and Civil Engineering, Research and Development, Biel, Switzerland

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objectives: In urine, aggregation (AGN) of crystal occurs although they are coated by negatively charged urinary macromolecules (UM) and isolated at a distance from each other, where attraction forces become extremely weak. Calcium (Ca) bridges or viscous binding by UM could explain this AGN. Methods: Suspensions of Ca oxalate monohydrate (COM) and carboxylated latex (CL) were prepared in buffered water and UM solutions which were obtained from the urine of 6 healthy men. Surface potential or zetapotential (ZP) of the particles was measured at various concentrations of Ca and UM. AGN of CL was monitored determining particle size and optical density. Results: The ZP of COM was neutralized by Ca and stabilized around –15 mV by UM. In CL, a stable ZP of about –20 mV was achieved at >3 mM Ca. However, to induce AGN further addition of Ca was necessary. AGN then increased independently of ZP with increasing Ca and decreased with increasing UM concentration. Conclusions: In CL, two different Ca effects could be distinguished, one on ZP and another on AGN. The latter is probably based on the formation of Ca bridges between particles and is inhibited by a steric barrier of adsorbed UM. A similar mechanism is postulated for crystal aggregation.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Baumann JM, Affolter B, Caprez U, Henze U: Calcium oxalate aggregation in whole urine, new aspects of calcium stone formation and metaphylaxis. Eur Urol 2003;43:421–425.
  2. Müller RH: Zetapotential und Partikelladung in der Laborpraxis. Stuttgart, Wissenschaftliche Verlagsgesellschaft mbH, 1996, vol 37.
  3. Khan SR, Kok DJ: Modulators of urinary stone formation. Front Biosci 2004;9:1450–1482.
  4. Khan SR, Finlayson B, Hacket RL: Stone matrix as proteins adsorbed on crystal surfaces: a microscopic study. Scanning Electron Microsc 1983;1:379–384.
  5. Baumann JM, Affolter B, Caprez U, Clivaz C, Glück Z, Weber R: Stabilization of calcium oxalate suspension by urinary macromolecules, probably an efficient protection from stone formation. Urol Int 2007;79:267–272.
  6. Wesson JA, Ganne V, Beshensky AM, Kleinmann JG: Regulation by macromolecules of calcium oxalate crystal aggregation in stone formers. Urol Res 2005;33:206–212.
  7. Asplin JR, Parks JH, Chen MS, Lieske JC, Toback FG, Pillay SN, Nakagawa Y, Coe FL: Reduced crystallization inhibition by urine from men with nephrolithiasis. Kidney Int 1999;56:1505–1516.
  8. Cao LC, Deng G, Boevè ER, de Bruijn WC, de Water R, Verkoelen CF, Romijn JC, Schroeder FH: Zeta potential measurement and particle size analysis for a better understanding of urinary inhibitors of calcium oxalate crystallization. Scanning Microsc 1996;10:401–414.
  9. Tiselius HG, Fornander AM, Nilsson MA: The effects of citrate and urine on calcium oxalate crystal aggregation. Urol Res 1993;21:363–366.
  10. Tiselius HG, Fornader AM, Nilsson MA: Effects of urinary macromolecules on the crystallization of calcium oxalate. Urol Res 1990;18:381–385.
  11. Hess B, Nakagawa Y, Coe FL: Inhibition of calcium oxalate monohydrate crystal aggregation by urine proteins. Am J Physiol Renal Fluid Electrolyte Physiol 1989;257:99–106.
  12. Scurr DS, Robertson WG: Modifiers of calcium oxalate crystallization found in urine. II. Studies on their mode of action in an artificial urine. J Urol 1986;136:128–131.
  13. Jaggi M, Nakagawa Y, Zipperle L, Hess B: Tamm-Horsfall protein in recurrent calcium kidney stone formers with positive family history: abnormalities in urinary excretion, molecular structure and function. Urol Res 2007;35:55–62.
  14. Webber D, Radcliffe CM, Royle L, Tobiasen G, Merry AH, Rodgers AL, Sturrock ED, Wormald MR, Harvay DJ, Dwek RA, Rudd PM: Sialylation of urinary prothrombin fragment 1 is implicated as a contributory factor in the risk of calcium oxalate kidney stone formation. FEBS J 2006;273:3024–3037.
  15. Hess B, Kok DJ: Nucleation, growth and aggregation of stone-forming crystals; in Coe FL, Favus MJ, Patt CYC, Parks JH, Preminger GM (eds): Kidney Stones: Medical and Surgical Management. Philadelphia, Lippincott-Raven Press, 1996, pp 3–32.
  16. Christmas KG, Gower LB, Khan SR, El-Shall H: Aggregation and dispersion characteristics of calcium oxalate monohydrate: effect of urinary species. J Colloid Interface Sci 2002;256:168–174.
  17. Baumann JM, Affolter B, Caprez U, Henze U, Lauper D, Maier F: Hydroxyapatite induction and secondary aggregation of calcium oxalate, two important processes in calcium stone formation. Urol Res 2001;29:417–422.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50